Title : Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.

Pub. Date : 2014 Dec

PMID : 25081321






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We demonstrate that Ibrutinib efficiently reduces the phosphorylation of the receptor tyrosine kinases ErbB1, ErbB2 and ErbB3, thereby suppressing AKT and MAPK signaling in ErbB2-positive (ErbB2+) breast cancer cell lines. ibrutinib AKT serine/threonine kinase 1 Homo sapiens